| Literature DB >> 33904234 |
Rachel E Szeghy1, Valesha M Province1, Nina L Stute1, Marc A Augenreich1, Laurel K Koontz1, Jonathon L Stickford1, Abigail S L Stickford1, Stephen M Ratchford1.
Abstract
NEWEntities:
Keywords: COVID-19; SARS-CoV-2; aortic augmentation index; carotid stiffness; intima-media thickness
Mesh:
Year: 2021 PMID: 33904234 PMCID: PMC8239784 DOI: 10.1113/EP089481
Source DB: PubMed Journal: Exp Physiol ISSN: 0958-0670 Impact factor: 2.858
Subject characteristics
| Characteristics | Control (5 male, 10 female) | SARS‐CoV‐2 (6 male, 9 female) |
| Hedge's |
|---|---|---|---|---|
| Subjects ( | 15 | 15 | – | – |
| Age (years) | 23 ± 1 | 20 ± 1 | <0.01 | 2.01 |
| Height (cm) | 168 ± 10 | 172 ± 11 | 0.48 | −0.38 |
| Weight (kg) | 63 ± 7 | 71 ± 13 | 0.11 | −0.71 |
| Body mass index (kg m−2) | 22 ± 2 | 24 ± 3 | 0.23 | −0.51 |
| Physical activity | ||||
| Frequency (days week−1) | 4 ± 2 | 4 ± 1 | 0.72 | 0.12 |
| Duration (min day−1) | 44 ± 15 | 41 ± 12 | 0.77 | 0.25 |
| Female contraceptive use ( | 4 | 5 | 0.44 | −0.54 |
Data are the mean ± SD. Student's two‐tailed t‐tests for two samples of equal variance were performed between control and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) groups.
FIGURE 1Severity of coronavirus disease 2019 symptoms. Subjects with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) self‐reported symptom severity on a scale of 0–100, with increasing severity, on the day of testing (n = 6 male and 8 female). One female subject with SARS‐CoV‐2 was asymptomatic and excluded from the figure. Data are the mean among individuals with SARS‐CoV‐2 symptoms
FIGURE 2Carotid stiffness (a), distensibility (b), compliance (c) and carotid Young's modulus of elasticity (d) in control subjects and subjects who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Student's two‐tailed t‐tests for two samples of equal variance were performed between the control (n = 5 male and 10 female) and SARS‐CoV‐2 (n = 6 male and 9 female) groups. * P < 0.05, between groups. Individual data are presented as open triangles (male subjects) and circles (female subjects) for the control group and filled triangles and circles for the SARS‐CoV‐2 group. Data are the mean ± SD
Carotid diameters and intima–media thickness
| Control | SARS‐CoV‐2 | |||
|---|---|---|---|---|
| Parameter | (5 male, 10 female) | (6 male, 9 female) |
| Hedge's |
| Mean diameter (mm) | 6.48 ± 0.49 | 6.78 ± 0.57 | 0.13 | −0.55 |
| Diastolic diameter (mm) | 6.31 ± 0.53 | 6.46 ± 0.55 | 0.45 | −0.27 |
| Systolic diameter (mm) | 6.64 ± 0.57 | 7.07 ± 0.59 | <0.05 | −0.73 |
| cIMT (mm) | 0.42 ± 0.06 | 0.44 ± 0.08 | 0.59 | −0.19 |
Data are the mean ± SD. Student's two‐tailed t‐tests for two samples of equal variance were performed between the control and SARS‐CoV‐2 groups. Abbreviations: cIMT, carotid intima–media thickness; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.
Central pressures and carotid pulse wave analysis measures
| Parameter | Control (5 male and 10 female) | SARS‐CoV‐2 (6 male and 9 female) |
| Hedge's |
|---|---|---|---|---|
| Peripheral carotid pressures | ||||
| Peripheral systolic pressure (mmHg) | 121 ± 12 | 129 ± 13 | 0.09 | −0.63 |
| Peripheral diastolic pressure (mmHg) | 70 ± 8 | 74 ± 7 | 0.20 | −0.47 |
| Peripheral pulse pressure (mmHg) | 51 ± 9 | 55 ± 10 | 0.20 | −0.47 |
| Peripheral mean arterial pressure (mmHg) | 87 ± 10 | 99 ± 8 | <0.01 | −1.17 |
| Central aortic pressures | ||||
| Central systolic pressure (mmHg) | 109 ± 14 | 124 ± 11 | <0.01 | −1.20 |
| Central diastolic pressure (mmHg) | 70 ± 9 | 74 ± 7 | 0.22 | −0.45 |
| Central pulse pressure (mmHg) | 38 ± 12 | 50 ± 7 | <0.01 | −1.63 |
| Central mean arterial pressure (mmHg) | 85 ± 11 | 99 ± 8 | <0.01 | −1.39 |
| Pulse wave analysis | ||||
| Heart rate period (ms) | 1,004 ± 235 | 898 ± 150 | 0.15 | 0.52 |
| Ejection duration (ms) | 333 ± 14 | 316 ± 17 | 0.01 | 1.07 |
| Ejection duration (%) | 35 ± 7 | 36 ± 4 | 0.55 | −0.22 |
| Aortic T2 | 219 ± 22 | 217 ± 44 | 0.82 | 0.08 |
| P1 Height (P1 − DP) | 34 ± 12 | 44 ± 8 | 0.02 | −0.90 |
| Aortic augmentation pressure (mmHg) | 1.0 ± 5.7 | 6.2 ± 4.7 | 0.01 | −0.97 |
| Aortic AIx (P2/P1; %) | 108 ± 13 | 116 ± 12 | 0.07 | −0.67 |
| Buckberg SEVR (%) | 162 ± 44 | 146 ± 27 | 0.25 | −0.41 |
| SPTI (mmHg s min−1) | 2,099 ± 447 | 2,429 ± 368 | 0.04 | −0.78 |
| DPTI (mmHg s min−1) | 3,239 ± 453 | 3,476 ± 333 | 0.12 | −0.58 |
| End systolic pressure (mmHg) | 98 ± 12 | 107 ± 9 | 0.03 | −0.82 |
| Mean systolic pressure (mmHg) | 101 ± 10 | 113 ± 10 | <0.01 | −1.12 |
| Mean diastolic pressure (mmHg) | 83 ± 9 | 90 ± 7 | 0.02 | −0.87 |
Data are the mean ± SD. Student's two‐tailed t‐tests for two samples of equal variance were performed between the control (and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) groups. Abbreviations: AIx, augmentation index; DP, diastolic pressure; DPTI, diastolic pressure–time index; P1, first systolic peak; P2, second systolic peak; SEVR, subendocardial viability ratio; STPI, systolic pressure–time index; T2, duration from the start of the pulse to the second systolic peak.
FIGURE 3Aortic augmentation index (a) and aortic augmentation index corrected for a heart rate of 75 beats min−1 (AIx@HR75; b) in control subjects and subjects who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Student's two‐tailed t‐tests for two samples of equal variance were performed between the control (n = 5 male and 10 female) and SARS‐CoV‐2 (n = 6 male and 9 female) groups. * P < 0.05, between groups. Individual data are presented as open triangles (male subjects) and circles (female subjects) for the control group and filled triangles and circles for the SARS‐CoV‐2 group. Data are the mean ± SD